[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nuvation Bio Inc (NUVB)

Nuvation Bio Inc (NUVB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,664,990
  • Shares Outstanding, K 347,597
  • Annual Sales, $ 62,900 K
  • Annual Income, $ -204,630 K
  • EBIT $ -213 M
  • EBITDA $ -211 M
  • 60-Month Beta 1.51
  • Price/Sales 26.58
  • Price/Cash Flow N/A
  • Price/Book 5.23

Options Overview Details

View History
  • Implied Volatility 71.18% (-9.80%)
  • Historical Volatility 54.42%
  • IV Percentile 1%
  • IV Rank 1.13%
  • IV High 369.46% on 03/27/26
  • IV Low 67.79% on 07/22/25
  • Expected Move (DTE 4) 0.43 (8.84%)
  • Put/Call Vol Ratio 0.50
  • Today's Volume 12
  • Volume Avg (30-Day) 604
  • Put/Call OI Ratio 0.40
  • Today's Open Interest 31,915
  • Open Int (30-Day) 31,213
  • Expected Range 4.39 to 5.24

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.25
  • Number of Estimates 4
  • High Estimate $-0.14
  • Low Estimate $-0.54
  • Prior Year $-0.17
  • Growth Rate Est. (year over year) -47.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.12 +16.63%
on 05/05/26
5.29 -9.17%
on 04/22/26
+0.20 (+4.46%)
since 04/10/26
3-Month
4.05 +18.79%
on 03/30/26
6.05 -20.58%
on 02/13/26
-0.91 (-16.00%)
since 02/11/26
52-Week
1.57 +206.05%
on 06/16/25
9.75 -50.72%
on 12/22/25
+2.71 (+129.90%)
since 05/09/25

Most Recent Stories

More News
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Nuvation Bio Inc. (NYSE: NUVB)

NEW YORK , May 7, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Nuvation Bio Inc. (NYSE: NUVB) on behalf of the company's shareholders. The investigation seeks to...

NUVB : 4.84 (+1.04%)
Nuvation Bio to Participate in Upcoming Investor Conferences

NEW YORK , May 5, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David...

NUVB : 4.84 (+1.04%)
Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update

Achieved $18.5 million in first quarter of 2026 net product revenues for IBTROZI ® (taletrectinib); majority of the approximately 200 patients started on IBTROZI in the first...

NUVB : 4.84 (+1.04%)
Can Nuvation Bio's Pipeline Finally Prove the Skeptics Wrong About Its Valuation?

Barchart Research What to Expect from NUVB Earnings NUVB Generated May 1, 2026 Current Price $4.49 EPS Estimate $$0.12 Consensus Rating Strong Buy Average Move 6.61% Can Nuvation Bio's Pipeline Finally...

NUVB : 4.84 (+1.04%)
Can Nuvation Bio's Pipeline Finally Prove the Skeptics Wrong About Its Valuation?

Barchart Research What to Expect from NUVB Earnings NUVB Generated May 1, 2026 Current Price $4.49 EPS Estimate $$0.12 Consensus Rating Strong Buy Average Move 6.61% Can Nuvation Bio's Pipeline Finally...

NUVB : 4.84 (+1.04%)
Can Nuvation Bio's Pipeline Finally Prove the Skeptics Wrong About Its Valuation?

Barchart Research What to Expect from NUVB Earnings NUVB Generated May 1, 2026 Current Price $4.49 EPS Estimate $$0.12 Consensus Rating Strong Buy Average Move 6.61% Can Nuvation Bio's Pipeline Finally...

NUVB : 4.84 (+1.04%)
Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers

Guidelines include the next-generation targeted therapy as a systemic option for patients with ROS1-positive non-small cell lung cancer with brain metastases

NUVB : 4.84 (+1.04%)
Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026

  Analysis of longer-term pooled data from TRUST-I and TRUST-II demonstrated nearly 50 months median duration of response and 46.1 months median progression-free survival in TKI-naïve patients

NUVB : 4.84 (+1.04%)
Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026

NEW YORK , April 20, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will...

NUVB : 4.84 (+1.04%)
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency

The Marketing Authorisation Application (MAA) has been validated and accepted for full approval consideration with a standard review timeline

NUVB : 4.84 (+1.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Nuvation Bio Inc. is a biopharmaceutical company. It engages in developing differentiated and novel therapeutic candidates for unmet needs in oncology. Nuvation Bio Inc., formerly known as Panacea Acquisition Corp., is based in NEW YORK.

See More

Key Turning Points

3rd Resistance Point 5.11
2nd Resistance Point 5.01
1st Resistance Point 4.90
Last Price 4.84
1st Support Level 4.69
2nd Support Level 4.59
3rd Support Level 4.48

See More

52-Week High 9.75
Fibonacci 61.8% 6.63
Fibonacci 50% 5.66
Last Price 4.84
Fibonacci 38.2% 4.69
52-Week Low 1.57

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.